Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
??9.65 +0.15 (+1.58%)
After hours: 04:29PM EDT?
Nice Pop...Thoughts on WHY?
https://www.foxnews.com/tech/researchers-ai-alzheimers-disease-identify-drug-targets
We all saw this coming. A whole new level of speculation...BUT, it is (might be) a faster process...they could have just asked Dr.M....IMO.
georgejji [quote]It is currently estimated that 6.7 million Americans have Alzheimer's disease
[/quote]
Imagine if each American who is currently a CNS- AD patient was treated w/A-273 , and consequently, did not require the intensive and expensive care systems now typically being used. These folks might spend a little time on the golf course, on the beach, playing a piano , reading books...living happy lives. BTW, as anyone might have witnessed, life in an AD or Hospice or memory care home or just lying around like a turnip on drugs is not a life. Not counting any RSD kids or their families.
So, the number of people who benefit from A2-73 treatments would also include their family members who are now having difficult lives torn apart daily by the various concerns and care processes in use. My guess is the real systemic number of lives being impacted by CNS diseases would easily exceed (6.7 million X 4) , close to 30 million in USA only.
So, close to 30 million Americans would directly benefit from an effective A2-73 (take one pill /day) process.
sab63090
quote link from Rubyred77...
So Many Dots, so little time...
'The S1R does not have a defined signaling pathway; instead, the dominant accepted model is that the S1R modulates other cellular signaling pathways by acting as a ligand-operated chaperone. (8) In fact, many protein–protein interactions involving S1R and other partners, such as voltage- or ligand-gated ion channels, GPCRs, transporters, or enzymes, have been identified, supporting its chaperone-like activity. (3) Importantly, the ability of S1R to homo- and heteromerize can be regulated by ligands. (9) Therefore, while S1R antagonists favor the formation of higher-order receptor oligomers, agonists promote the opposite, namely, the generation of lower-molecular-weight forms, such as homodimeric or monomeric receptors. In fact, the regulation of S1R oligomerization by ligands constitute the basis for considering this receptor as a ligand-operated chaperone. Specifically, at the interface between the endoplasmic reticulum (ER) and the mitochondrion (mitochondria-associated ER membrane, MAM), S1R interacts with the binding immunoglobulin protein (BiP), a resident chaperone of ER. (3,10-12) Specifically, S1R agonists or a reduction in ER calcium levels prompts the dissociation of S1R and BiP, which disclose the sole intrinsic chaperone activity of S1R and BiP with their respective client proteins. (8) Consistent with this, S1R is a calcium-sensitive chaperone located in the ER, specifically in the MAM, where it exerts an important role in stabilizing this interorganelle region, calcium homeostasis, mitochondrial bioenergetics, and ER stress response. (10,13) In addition, S1R can eventually translocate to the plasma membrane where it interacts with ion channels and GPCR. Finally, S1R can also be found in the nuclear envelope, where it regulates transcription. (10,11)"
The S1R does not have a defined signaling pathway; instead, the dominant accepted model is that the S1R modulates other cellular signaling pathways by acting as a ligand-operated chaperone. (8) In fact, many protein–protein interactions involving S1R and other partners, such as voltage- or ligand-gated ion channels, GPCRs, transporters, or enzymes, have been identified, supporting its chaperone-like activity. (3) Importantly, the ability of S1R to homo- and heteromerize can be regulated by ligands. (9) Therefore, while S1R antagonists favor the formation of higher-order receptor oligomers, agonists promote the opposite, namely, the generation of lower-molecular-weight forms, such as homodimeric or monomeric receptors. In fact, the regulation of S1R oligomerization by ligands constitute the basis for considering this receptor as a ligand-operated chaperone. Specifically, at the interface between the endoplasmic reticulum (ER) and the mitochondrion (mitochondria-associated ER membrane, MAM), S1R interacts with the binding immunoglobulin protein (BiP), a resident chaperone of ER. (3,10-12) Specifically, S1R agonists or a reduction in ER calcium levels prompts the dissociation of S1R and BiP, which disclose the sole intrinsic chaperone activity of S1R and BiP with their respective client proteins. (8) Consistent with this, S1R is a calcium-sensitive chaperone located in the ER, specifically in the MAM, where it exerts an important role in stabilizing this interorganelle region, calcium homeostasis, mitochondrial bioenergetics, and ER stress response. (10,13) In addition, S1R can eventually translocate to the plasma membrane where it interacts with ion channels and GPCR. Finally, S1R can also be found in the nuclear envelope, where it regulates transcription. (10,11)
https://pubs.acs.org/doi/full/10.1021/acschemneuro.3c00206#
sab63090
WGT....NO Doubt..."When...not IF".
Bourban OMCF...
plexrec...
Kevin,
Peter Senge is a "one of a kind" , brilliant teacher and model . IMO, if he were here he would be talking about..."What's next ? " This Precision Medicine thinking model , sounds like the next phase in our process of "problem solving" .
Kevindenver:
Agree, (gbrown6332) FDA are in a decades deep pit of failure created by their own poor leadership.
Anyone else think it is ODD that the normal AVXL pre-open chatter has been missing today? What's UP?
Find a way to accelerate the discovery/resolution process.
Many of us have experience working directly with regulatory bodies in resolving technical problems. Generally such bodies resist change of just about any kind. Changes often involve some level of risk management even rewriting the book of rules/guidance docs. No one wants to put their name on risky things or even be in the room when that discussion happens, never mind be the fool driving for change...they are ...."toe-less wonders".
We recognize that FDA top management are risk averse , they need to turn this into a strength ASAP. Other industries have done this. The MED-PHARMA -FDA need stop relying on statistical models to cover their AXXS and fix the science instead. They can begin by sitting in a room w/people like dr.M. and JUST LISTEN..
Too many innocent people have suffered and died already. Statistical models are being used to cover people's axxes. At this rate, we will all be dead before these guys get it.
I once helped a very brave & smart regulatory leader drive change which accelerated the rate at which highly complex semiconductor devices failed in military and commercial , space flight applications. The bio-physics were on the same level of complexity as these CNS-Bio-Pharma products and the consequences of failure were literally nuclear. If we look closely enough we will find other such examples in industry everywhere. Risk analysis/diagnosis tools-methods are how progress is made. Change is not a subject to turn away from when it is as obvious as this entire CNS regulatory body of work demonstrates.
First, Find a way to accelerate the RATE of failure in the LAB and then develop methods/science/techniques needed reduce/eliminate that root cause. Then prove effectiveness through zero risk application once the model is implemented through careful development of root cause analysis and then effective preventative techniques. (SEE Rome Air defense Center , RADC) development of HTRB as a mechanism to induce/cause failures in complex semiconductor devices and fire control and comm. systems.
Dr.M., if you read these messages, THEN LISTEN UP. I am a long time AVXL supporter holder who is nominally supportive of just about everything AVXL has done. I am running out of string though. We just have to make-get an economically and medically -effective viable CNS (AD) treatment out the door, NOW...not..SOME DAY, maybe.... NOW..., make that happen.
Within the past 30 days my identical twin brother passed away from complications of AD . He had the very best care available and in the end (IMO) he just gave up, after many falls, and complications typical of AD.
So my request is to take risks like you never dreamed you would and do whatever is needed to get this CNS treatment out the door and commercially available. BR...and I REALLY AM a NIDAN . Bless you and your team.
xodcode
8.72 +0.31 (+3.69%)
After hours: 04:28PM EDT...
Any thoughts on why this jump after hrs on Monday 5/8/23?
IMO, AVXL has taken a leadership position favoring RESTORATION to every human system and natural functions. FDA systems and methods have clearly failed to guide-direct or to lead.
J_K
$money bags$
8.40+0.06 (+0.72%)
At close: May 4 04:00PM EDT
8.57 +0.17 (+2.02%)
Pre-Market: 08:02AM EDT
IS $8.50 the MAGIC NUMBER OR NOT?...FCST suggests a showdown...
It's time for a little display -audition from the RSD...kids CHOIR signing their theme..."WE ARE THE WORLD".......RWD-RWE can be very effective when done well.
"This is not a drill". ..."Pilots and crews report to your Ready Rooms".... " Prepare the flight deck to commence Air Operations". ...
Lets all pray that AVXL-S1R becomes CNS systems solutions for those people who have been told..."Sorry, no effective treatments are available".
Just another good reason to own AVXL stock...feeling better already.
Tredenwater2
Any thoughts on todays AVXL Pre market lack of action shown??
Anavex Life Sciences Corp. (AVXL)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
Visitors trend2W10W9M
Quote Lookup
8.34+0.34 (+4.25%)
At close: May 3 04:00PM EDT
8.34 0.00 (0.00%)
Pre-Market: 07:15AM EDT
AVXL staff and shareholders are now experiencing our own..."Petri Dish (anti-biotic) Moment". It may take months before the proof-dust settles but it will settle eventually. We should not expect the entire R.O.W. to "Get It" right out of the chute ...many will resist/others will present variations/alternatives ...AKA , "Snake oil".
I predict that the OFFICIAL DECLARATION of the END (DAS ENDE) to the CURSE OF AD can be expected w/in a few days/weeks months....FINALLY then a new way of LONGER, HAPPIER, MORE COMPLETE life may begin for all.
https://finance.yahoo.com/news/lillys-donanemab-significantly-slowed-cognitive-100000337.html?.tsrc=fin-srch
Infusion based treatment . Beating same ole Amyloid pony.
Thanks for posting this georgejji,
Tredenwater2
bas2020...
sumbuysumsell
Any thoughts or hard evidence on what the trading pattern means/suggests this AM?. Jumpy sp, w/lots of small qty buys?
BINGO...Jimmy _ mcyoloswag...S1R is a winner and a recurring key in the human systems being interactively-systemically linked (key words... CNS systems all linked). Heart, brain, key organs are each wired to and Bio controlled by human situational reaction to STRESS. BINGO, it all makes sense. We are on the right track. IMO, S1R is the recurring Bio-chem link. (only a matter of time until CNS Bio-MED DOTS start connecting).
"Blarcamesine, for the heart and for the soul" :
https://academic.oup.com/cardiovascres/article/93/1/6/415113?login=false
Treden...I believe it would be appropriate to consider that every fiber in our human CNS links are actually mini-micro conducting elements used for micro-trigger-bio impulses (some micro-bio induced) and that these micro-fiber links are not being given the credit-recognition they should get. (ask falconer how nerves are linked-communicate). It is the only plausible explanation for how(when we snub a toe) the pain signal gets to the right place in the brain and we react, we even know which toe was hurt. There must be an effective (electro-bio-chem.)micro linkage system to make all this happen. IMO, we are already prewired like a computer but in some (rare)cases those links are not set correctly -broken-blocked-deteriorated..etc. . In my simple thesis we are all a bundle of micro fiber links , some work better then others. S1R, is the Juice.
In my simple minded CNS model S1R (see falconer) links and micro bio must work in a balanced systems manner or you will miss that 3ft put every time.
So, the Central nervous System processor needs to have effective links which allow the brain to do-drive-signal the required control functions. Much bigger system than my simple model . The point is , we are all systems w/links, S1R is a critical micro-bio glue to make it work .effectively (IMO).
SO MANY DOTS, SO LITTLE TIME..."SYSTEMS HAPPEN".
Falconer66a...
Eventually , S1R may be seen as Nature's Secret Sauce for AVXL , "Wonder Juice".
[quoteAnavex Life Sciences Corp.
Anavex Life Sciences Corp.
NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, announced today it was granted a new U.S. Patent No. 11,622,955 entitled “SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY,” from the United States Patent and Trademark Office (USPTO), expanding Anavex’s coverage of treatment methods for ANAVEX®2-73 (blarcamesine), to the treatment of systolic hypertension, or lowering systolic blood pressure.
“We are extremely pleased with the expansion of the patent portfolio for ANAVEX®2-73 (blarcamesine) for the indication of hypertension which affects nearly half (47%) of adults in the United States, especially since elevated systolic blood pressure is a major health economy problem within our aging society,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “This new patent will add to our already robust patent portfolio relating to ANAVEX®2-73, and further demonstrate our strong overall commitment to protecting the full range of commercial opportunities of our product portfolio.”][/quote]